atorvastatin has been researched along with Diabetic Angiopathies in 48 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.08) | 18.2507 |
| 2000's | 29 (60.42) | 29.6817 |
| 2010's | 18 (37.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cummings, JL; Ginsberg, HD; Johansson, JO; Kalantar-Zadeh, K; Kulikowski, E; Nicholls, SJ; Ray, KK; Schwartz, GG; Sweeney, M; Toth, PP; Wong, N | 1 |
| Czitrom, D; Ennezat, PV; Le Jemtel, TH; Malergue, MC; Maréchaux, S; Tricot, O; Vincentelli, A | 1 |
| Feng, B; Li, X; Wang, H; Xu, L | 1 |
| Adamson, U; Jörneskog, G; Lins, PE; Mobarrez, F; Tehrani, S; Wallén, HN | 1 |
| Bhansali, A; Jani, RH; Jariwala, G; Jha, P; Joshi, S; Mukhopadhyay, S; Pai, V | 1 |
| Eleftheriadou, I; Grigoropoulou, P; Katsilambros, N; Makrilakis, K; Margeli, A; Papassotiriou, I; Perrea, D; Tentolouris, N; Zoupas, C | 1 |
| Ballantyne, CM; Barter, PJ; Chapman, MJ; Erbel, R; Kataoka, Y; Libby, P; Nicholls, SJ; Nissen, SE; Puri, R; Raichlen, JS; Shao, M; Uno, K | 1 |
| Bao, W; Betteridge, DJ; Charlton-Menys, V; Colhoun, HM; DeMicco, DA; Durrington, PN; Fuller, JH; Hitman, GA; Livingstone, SJ; Neil, HA; Preston, GM; Schalkwijk, CG; Soedamah-Muthu, SS; Stehouwer, CD | 1 |
| Bergen, K; Brismar, K; Tehrani, S | 1 |
| Colin, X; Lafuma, A; Solesse, A | 1 |
| Ballantyne, CM; Cain, VA; Raichlen, JS | 1 |
| Betteridge, DJ; Charlton-Menys, V; Colhoun, H; DeMicco, DA; Durrington, PN; France, M; Fuller, J; Hitman, GA; Livingstone, SJ; Neil, HA; Newman, CB; Szarek, M | 1 |
| Farmer, A; Holman, RR; Neil, HA; Paul, S; Stratton, IM; Tucker, L | 1 |
| Glinkina, IV; Il'in, AV; Mel'nichenko, GA; Roĭtman, AP; Zilov, AV | 1 |
| Haller, MJ; Pepine, C; Samyn, MM; Shuster, JJ; Silverstein, JH; Stein, JM; Theriaque, D | 1 |
| Annemans, L; Marbaix, S; Scheen, A; Van Gaal, L; Webb, K | 1 |
| Bays, H; Bird, S; Conard, S; Hanson, ME; Leiter, LA; Lin, J; Shah, A; Tershakovec, AM | 1 |
| Atkin, SL; Kilpatrick, ES; Sathyapalan, T | 1 |
| Higa, M; Masuzaki, H; Shimabukuro, M; Shimabukuro, T; Tanaka, H; Yamakawa, K | 1 |
| Budinski, D; Gosho, M; Gumprecht, J; Hounslow, N | 1 |
| Drechsler, C; Genser, B; Hoffmann, MM; März, W; Wanner, C | 1 |
| Cho, HJ; Kim, HS; Kim, SJ; Kwon, YW; Lee, HY; Lee, SW; Oh, BH; Park, YB; Youn, SW | 1 |
| Brudi, P; Hanson, ME; Jimenez, JG; Massaad, R; Pirags, V; Rosen, JB; Triscari, J | 1 |
| Brudi, P; Hanson, ME; Jimenez, JG; Massaad, R; McPeters, G; Pirags, V; Rosen, JB; Triscari, J; Vides, H | 1 |
| Brandle, M; Davidson, MB; Herman, WH; Lorber, B; Schriger, DL | 1 |
| Betteridge, DJ; Colhoun, HM; Durrington, PN; Fuller, JH; Hitman, GA; Livingstone, SJ; Mackness, MI; Neil, HA; Thomason, MJ | 1 |
| Isley, WL | 1 |
| Ganda, OP | 1 |
| Griebenow, R | 1 |
| Owen, OG | 1 |
| Eisenbarth, GS | 1 |
| McFarlane, SI; Murad, O; Palmer, J; Sowers, J | 1 |
| Matsui, T; Nakamura, K; Yamagishi, S | 1 |
| Charlton-Menys, V; Durrington, P | 1 |
| Barter, P; Breazna, A; Carmena, R; Deedwania, P; Fruchart, JC; Grundy, S; Haffner, S; Hsia, J; LaRosa, J; Shepherd, J; Waters, D | 1 |
| Kimura, M; Okamura, A; Takahashi, M; Takano, T; Yamakawa, T | 1 |
| Krane, V; Wanner, C | 1 |
| Inoue, H; Matsui, T; Nakamura, K; Yamagishi, S | 1 |
| Allen, C; Chung, N; Constance, C; Johnson-Levonas, AO; Lund, M; Massaad, R; McCrary Sisk, C; Westphal, S | 1 |
| Dhayat, N; Dhayat, S; Du, J; Hilfiker-Kleiner, D; Laufs, U; Noutsias, M; Riad, A; Schultheiss, HP; Spillmann, F; Tschöpe, C; Van Linthout, S; Westermann, D | 1 |
| Betteridge, DJ; Colhoun, H; Durrington, PN; Fuller, J; Hitman, GA; Livingstone, S; Neil, HA; Newman, C; Szarek, M | 1 |
| Cieslik, G; Fedak, D; Galicka-Latala, D; Konduracka, E; Naskalski, J; Piwowarska, W; Rostoff, P; Sieradzki, J | 1 |
| Bauersachs, J; Brandt, M; Closs, E; Daiber, A; Ertl, G; Förstermann, U; Münzel, T; Oelze, M; Thum, T; Wenzel, P; Xu, J; Zou, MH | 1 |
| Caulin-Glaser, T; Falko, JM; Meis, SB; Moser, RJ | 1 |
| Gänzer, H; Kirchmair, R; Patsch, JR; Sturm, W | 1 |
| Arnaboldi, L; Bellosta, S; Bernini, F; Corsini, A; Ferri, N; Paoletti, R | 1 |
7 review(s) available for atorvastatin and Diabetic Angiopathies
| Article | Year |
|---|---|
[Benefit of elective percutaneous coronary intervention for stable coronary artery disease].
Topics: Age Factors; Angina Pectoris; Atorvastatin; Coronary Artery Disease; Diabetic Angiopathies; Elective Surgical Procedures; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Meta-Analysis as Topic; Percutaneous Coronary Intervention; Placebo Effect; Randomized Controlled Trials as Topic; Reoperation; Stents; Surgical Procedures, Operative; Treatment Outcome | 2019 |
The role of lipid management in diabetes.
Topics: Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus; Diabetic Angiopathies; Gemfibrozil; Heptanoic Acids; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lipoproteins, HDL; Pyrroles; Simvastatin; Triglycerides | 2005 |
Statins and CVD prevention in the diabetic population: implications of the CARDS trial.
Topics: Atorvastatin; Cardiovascular Diseases; Coronary Disease; Diabetes Mellitus; Diabetic Angiopathies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Randomized Controlled Trials as Topic; Survival Analysis | 2005 |
Atorvastatin and diabetic vascular complications.
Topics: Anticholesteremic Agents; Atorvastatin; Diabetic Angiopathies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Pyrroles | 2006 |
Apolipoproteins AI and B as therapeutic targets.
Topics: Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins B; Atorvastatin; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Clinical Trials as Topic; Clofibric Acid; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Heptanoic Acids; Humans; Lipoproteins; Lipoproteins, LDL; Postprandial Period; Pyrroles | 2006 |
Cardiovascular disease risk of type 2 diabetes mellitus and metabolic syndrome: focus on aggressive management of dyslipidemia.
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dyslipidemias; Heptanoic Acids; Humans; Metabolic Syndrome; Niacin; Pyrroles; Triglycerides; United States | 2005 |
[Statins in diabetic hyperlipidemia].
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Pyrroles; Risk Factors; Triglycerides | 1999 |
25 trial(s) available for atorvastatin and Diabetic Angiopathies
| Article | Year |
|---|---|
Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trial.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Drug Administration Schedule; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proteins; Quinazolinones; Renal Insufficiency, Chronic; Renin-Angiotensin System; Rosuvastatin Calcium; Stroke; Treatment Outcome | 2019 |
Impaired endothelium-dependent skin microvascular function during high-dose atorvastatin treatment in patients with type 1 diabetes.
Topics: Administration, Cutaneous; Adult; Atorvastatin; Biomarkers; Cell-Derived Microparticles; Cross-Over Studies; Diabetes Mellitus, Type 1; Diabetic Angiopathies; Double-Blind Method; Dyslipidemias; Endothelium, Vascular; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Iontophoresis; Laser-Doppler Flowmetry; Male; Microcirculation; Middle Aged; Pyrroles; Risk Factors; Skin; Sweden; Time Factors; Treatment Outcome; Vasodilator Agents | 2013 |
A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of Saroglitazar 2 and 4 mg compared with placebo in type 2 diabetes mellitus patients having hypertriglyceridemia not controlled with atorvastatin therapy (PRES
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Fasting; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Male; Middle Aged; Patient Safety; Phenylpropionates; Prospective Studies; Pyrroles; Risk Reduction Behavior; Treatment Failure; Treatment Outcome; Triglycerides | 2014 |
Effect of atorvastatin on baroreflex sensitivity in subjects with type 2 diabetes and dyslipidaemia.
Topics: Aged; Atorvastatin; Baroreflex; Body Mass Index; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Cardiomyopathies; Diet, Fat-Restricted; Dyslipidemias; Female; Greece; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myalgia; Obesity; Patient Dropouts; Prospective Studies; Pyrroles; Risk Factors | 2014 |
Effect of atorvastatin on C-reactive protein and benefits for cardiovascular disease in patients with type 2 diabetes: analyses from the Collaborative Atorvastatin Diabetes Trial.
Topics: Adult; Aged; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged | 2015 |
High-dose atorvastatin is associated with lower IGF-1 levels in patients with type 1 diabetes.
Topics: Acetylcholine; Adult; Atorvastatin; Cross-Over Studies; Diabetes Mellitus, Type 1; Diabetic Angiopathies; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin-Like Growth Factor Binding Protein 1; Insulin-Like Growth Factor I; Iontophoresis; Laser-Doppler Flowmetry; Male; Microcirculation; Middle Aged; Nitroprusside; Risk Factors; Skin; Vasodilation; Vasodilator Agents | 2016 |
Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: the MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvas
Topics: Aged; Apolipoproteins B; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetic Angiopathies; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Linear Models; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2008 |
Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: the Collaborative Atorvastatin Diabetes Study (CARDS).
Topics: Adult; Aged; Apolipoprotein A-I; Apolipoproteins; Atorvastatin; Biomarkers; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Female; Heart Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pyrroles; Risk Factors; Triglycerides | 2009 |
Atorvastatin in Factorial with Omega-3 EE90 Risk Reduction in Diabetes (AFORRD): a randomised controlled trial.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Body Size; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Patient Selection; Placebos; Pyrroles | 2009 |
[Comparison of the effects of carbohydrate metabolism compensation and atorvastatin treatment on lipid metabolism and C-reactive protein in type 2 diabetes mellitus].
Topics: Atorvastatin; C-Reactive Protein; Carbohydrate Metabolism; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Lipids; Male; Middle Aged; Pyrroles | 2008 |
Pediatric Atorvastatin in Diabetes Trial (PADIT): a pilot study to determine the effect of atorvastatin on arterial stiffness and endothelial function in children with type 1 diabetes mellitus.
Topics: Adolescent; Adult; Anticholesteremic Agents; Atorvastatin; Child; Cross-Over Studies; Diabetes Mellitus, Type 1; Diabetic Angiopathies; Double-Blind Method; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Male; Patient Compliance; Peripheral Vascular Diseases; Pilot Projects; Placebos; Pyrroles; Radial Artery; Vascular Resistance; Young Adult | 2009 |
Ezetimibe added to atorvastatin compared with doubling the atorvastatin dose in patients at high risk for coronary heart disease with diabetes mellitus, metabolic syndrome or neither.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Canada; Coronary Artery Disease; Diabetic Angiopathies; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Metabolic Syndrome; Middle Aged; Pyrroles; Risk Factors; Treatment Outcome; United States; Young Adult | 2010 |
Distinct effects of pitavastatin and atorvastatin on lipoprotein subclasses in patients with Type 2 diabetes mellitus.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoproteins; Male; Middle Aged; Pyrroles; Quinolines; Treatment Outcome | 2011 |
Comparative long-term efficacy and tolerability of pitavastatin 4 mg and atorvastatin 20-40 mg in patients with type 2 diabetes mellitus and combined (mixed) dyslipidaemia.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Quinolines; Treatment Outcome; Young Adult | 2011 |
Lack of association between the Trp719Arg polymorphism in kinesin-like protein-6 and cardiovascular risk and efficacy of atorvastatin among subjects with diabetes on dialysis: the 4D study.
Topics: Aged; Analysis of Variance; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Double-Blind Method; Female; Genetic Predisposition to Disease; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinesins; Logistic Models; Male; Middle Aged; Phenotype; Polymorphism, Genetic; Proportional Hazards Models; Prospective Studies; Pyrroles; Renal Dialysis; Risk Assessment; Risk Factors; Treatment Outcome | 2011 |
The efficacy and safety of ezetimibe/simvastatin combination compared with intensified lipid-lowering treatment strategies in diabetic subjects with and without metabolic syndrome.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Azetidines; Blood Glucose; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Ezetimibe, Simvastatin Drug Combination; Fasting; Female; Fluorobenzenes; Heptanoic Acids; Humans; Male; Metabolic Syndrome; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2013 |
A comparison of efficacy and safety of an ezetimibe/simvastatin combination compared with other intensified lipid-lowering treatment strategies in diabetic patients with symptomatic cardiovascular disease.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Complications; Diabetic Angiopathies; Double-Blind Method; Drug Combinations; Drug Monitoring; Ezetimibe, Simvastatin Drug Combination; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hypercholesterolemia; Longitudinal Studies; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Severity of Illness Index; Simvastatin; Sulfonamides | 2013 |
Baseline characteristics in the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with Type 2 diabetes.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Triglycerides | 2004 |
The collaborative atorvastatin diabetes study: preliminary results.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Prospective Studies; Pyrroles | 2005 |
Statin treatment of patients with diabetes.
Topics: Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles | 2005 |
Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study.
Topics: Aged; Atorvastatin; Blood Pressure; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Triglycerides | 2006 |
Lessons learnt from the 4D trial.
Topics: Atorvastatin; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Placebos; Pyrroles; Renal Dialysis | 2006 |
Efficacy of ezetimibe/simvastatin 10/20 and 10/40 mg compared with atorvastatin 20 mg in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Body Mass Index; Cholesterol; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Ezetimibe; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Simvastatin; Triglycerides | 2007 |
Stroke prediction and stroke prevention with atorvastatin in the Collaborative Atorvastatin Diabetes Study (CARDS).
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Lipoproteins; Male; Middle Aged; Pyrroles; Risk Factors; Stroke | 2007 |
Effect of atorvastatin on endothelial function and inflammation in long-duration type 1 diabetic patients without coronary heart disease and arterial hypertension.
Topics: Adult; Atorvastatin; Brachial Artery; Coronary Artery Disease; Diabetes Mellitus, Type 1; Diabetic Angiopathies; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Pyrroles; Vasodilation; von Willebrand Factor | 2008 |
16 other study(ies) available for atorvastatin and Diabetic Angiopathies
| Article | Year |
|---|---|
Multiple statistical methods for assessing differential gene expression in microarray data of diabetic model rats to predict the molecular mechanism of atorvastatin on anti-atherogenesis.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Data Interpretation, Statistical; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Gene Expression Profiling; Heptanoic Acids; Male; Microarray Analysis; Prognosis; Pyrroles; Rats; Rats, Sprague-Dawley; Rats, Wistar; Streptozocin; Treatment Outcome | 2013 |
Sex-related differences of coronary atherosclerosis regression following maximally intensive statin therapy: insights from SATURN.
Topics: Aged; Atorvastatin; C-Reactive Protein; Comorbidity; Coronary Artery Disease; Diabetic Angiopathies; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sex Factors; Sulfonamides; Ultrasonography, Interventional | 2014 |
[Dual cholesterol inhibition. More high risk patients achieve LDL cholesterol values below 100 mg/dl].
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Disease; Diabetic Angiopathies; Drug Therapy, Combination; Ezetimibe; Germany; Heptanoic Acids; Humans; Hypercholesterolemia; Multicenter Studies as Topic; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin | 2008 |
Cost-effectiveness of atorvastatin in the prevention of cardiovascular events in diabetic patients: a French adaptation of CARDS.
Topics: Atorvastatin; Cardiovascular Diseases; Cost-Benefit Analysis; Diabetic Angiopathies; France; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Primary Prevention; Pyrroles | 2008 |
Cost effectiveness of atorvastatin in patients with type 2 diabetes mellitus: a pharmacoeconomic analysis of the collaborative atorvastatin diabetes study in the belgian population.
Topics: Aged; Atorvastatin; Belgium; Cardiovascular Diseases; Cholesterol, HDL; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drugs, Generic; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insurance, Health, Reimbursement; Male; Markov Chains; Middle Aged; Models, Economic; Models, Statistical; Pyrroles; Quality-Adjusted Life Years; Triglycerides | 2010 |
Low density lipoprotein-cholesterol variability in patients with type 2 diabetes taking atorvastatin compared to simvastatin: justification for direct measurement?
Topics: Aged; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Half-Life; Heptanoic Acids; Humans; Hypercholesterolemia; Lipid Metabolism; Male; Middle Aged; Pyrroles; Simvastatin; Treatment Outcome | 2010 |
FOXO1 impairs whereas statin protects endothelial function in diabetes through reciprocal regulation of Kruppel-like factor 2.
Topics: Animals; Atorvastatin; Base Sequence; Binding Sites; Blood Glucose; Cells, Cultured; Chromatin Immunoprecipitation; Cytoprotection; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelium, Vascular; Forkhead Box Protein O1; Forkhead Transcription Factors; Gene Expression Regulation; Heptanoic Acids; Human Umbilical Vein Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kruppel-Like Transcription Factors; Male; Mevalonic Acid; Molecular Sequence Data; Nerve Tissue Proteins; Nitric Oxide Synthase Type III; Phosphorylation; Promoter Regions, Genetic; Pyrroles; Rats; Rats, Inbred OLETF; RNA Interference; Time Factors; Transfection; Vasodilation; Vasodilator Agents | 2013 |
Cost effectiveness of statin therapy for the primary prevention of major coronary events in individuals with type 2 diabetes.
Topics: Atorvastatin; Cholesterol, LDL; Coronary Disease; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Reproducibility of Results; Sensitivity and Specificity; Simvastatin; United States | 2003 |
What did PROVE-IT prove?
Topics: Anticholesteremic Agents; Atorvastatin; Diabetic Angiopathies; Heptanoic Acids; Humans; Myocardial Infarction; Pravastatin; Pyrroles; Reproducibility of Results; Thrombolytic Therapy | 2004 |
[The CARDS Study: cardiovascular primary prevention in diabetes patients using Atorvastin].
Topics: Anticholesteremic Agents; Atorvastatin; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Heptanoic Acids; Humans; Multicenter Studies as Topic; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Stroke; Treatment Outcome | 2005 |
Influences of statins on glucose tolerance in patients with type 2 diabetes mellitus.
Topics: Aged; Atorvastatin; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glucose Tolerance Test; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypoglycemic Agents; Male; Middle Aged; Pravastatin; Pyrroles; Retrospective Studies | 2006 |
High-dose statins for diabetes.
Topics: Atorvastatin; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles | 2006 |
A novel pleiotropic effect of atorvastatin on advanced glycation end product (AGE)-related disorders.
Topics: Atorvastatin; Diabetic Angiopathies; Glycation End Products, Advanced; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles | 2007 |
Anti-inflammatory effects of atorvastatin improve left ventricular function in experimental diabetic cardiomyopathy.
Topics: Animals; Anti-Inflammatory Agents; Atorvastatin; Collagen; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetic Angiopathies; Heart; Heptanoic Acids; Inflammation; Myocardium; Pyrroles; Rats; Rats, Sprague-Dawley; Ventricular Dysfunction, Left; Ventricular Function, Left | 2007 |
Mechanisms underlying recoupling of eNOS by HMG-CoA reductase inhibition in a rat model of streptozotocin-induced diabetes mellitus.
Topics: Animals; Atorvastatin; Biopterins; Body Weight; Cell Adhesion Molecules; Cytochrome P-450 Enzyme System; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetic Angiopathies; Disease Models, Animal; Endothelium, Vascular; Enzyme Activation; GTP Cyclohydrolase; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intramolecular Oxidoreductases; Male; Microfilament Proteins; NADH, NADPH Oxidoreductases; NADPH Oxidase 1; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Oxidative Stress; Phosphoproteins; Pyrroles; Rats; Rats, Wistar; Stem Cells; Tetrahydrofolate Dehydrogenase; Vasodilation | 2008 |
Pleiotropic effects of statins in atherosclerosis and diabetes.
Topics: Animals; Arteriosclerosis; Atorvastatin; Cell Division; Cell Movement; Cells, Cultured; Cholesterol; Cholesterol Esters; Diabetes Complications; Diabetes Mellitus; Diabetic Angiopathies; Endocytosis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lipoproteins; Lovastatin; Macrophages; Macrophages, Peritoneal; Mice; Mice, Inbred BALB C; Muscle, Smooth; Pyridines; Pyrroles; Simvastatin | 2000 |